
LENZ Stock Forecast & Price Target
LENZ Analyst Ratings
Bulls say
LENZ Therapeutics is benefiting from clear early commercial traction, with VIZZ sales rising 53% quarter over quarter to $2.6MM and paid prescriptions topping 38K, while more than 15K unique prescribers and 75% repeat writers suggest strong clinician acceptance. The investment case is further supported by VIZZ’s differentiated aceclidine mechanism, rapid onset, and all-day durability up to 10 hours, alongside refill and retention signals such as over 60% of e-pharmacy patients buying more than one monthly pack since launch. Management’s strategic reorganization, telehealth emphasis, and projected 2027 annualized operating expense reduction of greater than 50% improve operating leverage, even as consumer marketing remains the key growth engine.
Bears say
LENZ Therapeutics is facing a weaker-than-expected commercial launch, with 3Q26 revenues of $3.4M versus $4.2M consensus and $6.0M estimated, while SG&A rose to $35.8M and the company posted a $31.0M net loss, or $0.99 per diluted share. The balance sheet shows $197.3M in cash and equivalents as of September 30, 2026, but that cushion is being consumed by ongoing operating losses and uncertain near-term monetization. Investor sentiment is further pressured by a December 2025 FAERS retinal tear report for VIZZ, which amplifies clinical, regulatory, and commercialization risk while management is still dependent on awareness and Rx growth to restore confidence.
This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LENZ Analyst Forecast & Price Prediction
Start investing in LENZ
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About LENZ Therapeutics Inc (LENZ) Forecast
LENZ Analyst Forecast & Price Prediction
Start investing in LENZ
Order type
Buy in
Order amount
Est. shares
0 shares